Delivery Order 36F79719D0160-36C24526N0322

The Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a $19,549.38 firm fixed-price delivery order to Catalyst Pharmaceuticals, Inc. for the supply of Firdapse 10 mg tablets. The contract, awarded on February 12, 2026, with an ultimate completion date of February 16, 2026, was issued without a set-aside designation. Performance will be conducted at the contractor's facility in Bartlett, Tennessee. This delivery order is placed against Catalyst Pharmaceuticals' existing $5.5 million Blanket Purchase Agreement with the Veterans Health Administration National Acquisition Center, established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and effective through July 25, 2026.

Catalyst Pharmaceuticals, a for-profit pharmaceutical company headquartered in Coral Gables, Florida, specializes in rare disease therapies and has established itself as a primary supplier of Firdapse to the VA system. Firdapse (amifampridine) is an FDA-approved treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune neuromuscular disorder. The contractor's federal portfolio demonstrates sustained engagement with the VA across multiple delivery orders since 2021, totaling approximately $854,000 in combined ceiling values. The BPA structure enables multiple Veterans Integrated Service Networks to place individual delivery orders, streamlining procurement and ensuring consistent product availability across the VA healthcare system while maintaining compliance with statutory pricing requirements through annual public law updates.